Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 10/2017

01-10-2017 | Food for Thought

A systematic review of the barriers affecting medication adherence in patients with rheumatic diseases

Authors: Hendra Goh, Yu Heng Kwan, Yi Seah, Lian Leng Low, Warren Fong, Julian Thumboo

Published in: Rheumatology International | Issue 10/2017

Login to get access

Abstract

Medication adherence is a crucial part in the management of rheumatic diseases, especially with many such patients requiring long-term medications. In this paper, we aim to systematically review the literature for the factors associated with medication adherence in the rheumatic patient population. We carried out a systematic literature search using PubMed®, PsychInfo® and Embase ® with relevant keywords and employed the PRISMA® criteria. We included English peer-reviewed articles that studied the factors affecting medication adherence in patients with rheumatic diseases, which were assessed by two independent reviewers. Hand searches were conducted and relevant factors were extracted and classified using the World Health Organization (WHO)’s five dimensions of medication adherence. A simple diagram was drawn to summarise the factors extracted. 1977 articles were identified and reviewed and 90 articles were found to be relevant. A total of 17 factors and 38 sub-factors were identified and categorized based on the WHO’s five dimensions of medication adherence. A hand model for medication adherence was developed to succinctly summarise these dimension to remind clinicians the importance of medication adherence in daily practice. We conducted a systematic review on the various factors including patient, therapy, condition, health system and socioeconomic-related factors that affected medication adherence in rheumatic patients. We found 17 factors and 38 sub-factors that affected medication adherence in this population. This systematic review can facilitate future focused research in unexplored dimensions.
Appendix
Available only for authorised users
Literature
1.
Greenstein B, Greenstein A (2007) Concise clinical pharmacology. Pharmaceutical Press, London, p 102
2.
3.
4.
Hoving JL, Lacaille D, Urquhart DM, Hannu TJ, Sluiter JK, Frings-Dresen MH (2014) Non-pharmacological interventions for preventing job loss in workers with inflammatory arthritis. The Cochrane database of systematic reviews. Cd010208
5.
Smolen JS, Breedveld FC, Burmester GR et al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3–15CrossRefPubMed
6.
Zomahoun HT, Guenette L, Gregoire JP et al (2016) Effectiveness of motivational interviewing interventions on medication adherence in adults with chronic diseases: a systematic review and meta-analysis. Int J Epidemiol 46(2):589–602
7.
Krueger KP, Berger BA, Felkey B (2005) Medication adherence and persistence: a comprehensive review. Adv Ther 22:313–356CrossRefPubMed
8.
De Geest S, Sabate E (2003) Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs 2:323CrossRefPubMed
9.
Wabe N, Lee A, Wechalekar M, McWilliams L, Proudman S, Wiese M (2017) Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users. Rheumatol Int 6(37):897–904CrossRef
10.
de Achaval S, Suarez-Almazor ME (2010) Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumatol 5:313–326CrossRef
11.
Burkhart PV, Sabate E (2003) Adherence to long-term therapies: evidence for action. J Nurs Scholarsh 35:207PubMed
12.
Bernatsky S, Ehrmann Feldman D (2008) Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: analysis of administrative health databases in Québec, Canada. Drugs Aging 25:879–884CrossRefPubMed
13.
Brandstetter S, Hertig S, Loss J, Ehrenstein B, Apfelbacher C (2016) The lesser of two evils…’—views of persons with rheumatoid arthritis on medication adherence: a qualitative study. Psychol Health 31:675–692CrossRefPubMed
14.
Bruera S, Barbo AG, Lopez-Olivo MA (2016) Use of medication reminders in patients with rheumatoid arthritis. Rheumatol Int 36:1543–1548CrossRefPubMed
15.
Brus H, van de Laar M, Taal E, Rasker J, Wiegman O (1999) Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations. Patient Educ Couns 36:57–64CrossRefPubMed
16.
Bugni VM, Ozaki LS, Okamoto KY et al (2012) Factors associated with adherence to treatment in children and adolescents with chronic rheumatic diseases. J Pediatria 88:483–488CrossRef
17.
Choi JY, Cho SK, Choi CB et al (2014) The risk factors for nonadherence to anti-rheumatic treatment in patients with rheumatoid arthritis. Ann Rheumatic Dis 73(Suppl 2):913
18.
Chu LH, Kawatakar AA (2012) Long term medication adherence of adalimumab and etanercept among rheumatoid arthritis patients in Kaiser Permanente Southern California. Value Health 15:A40CrossRef
19.
Dalbeth N, Petrie KJ, House M et al (2011) Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care Res 63:1605–1612CrossRef
20.
De Cuyper E, De Gucht V, Maes S, Van Camp Y, De Clerck LS (2016) Determinants of methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol 35:1335–1339CrossRefPubMed
21.
Denoeud L, Mazieres B, Payen-Champenois C, Ravaud P (2005) First line treatment of knee osteoarthritis in outpatients in France: adherence to the EULAR 2000 recommendations and factors influencing adherence. Ann Rheum Dis 64:70–74CrossRefPubMedPubMedCentral
22.
Ekşioǧlu E, Çakir B, Gürçay E, Çakci A (2005) Factors affecting medical treatment compliance in one-year follow up of rheumatoid arthritis patients. J Rheumatol Med Rehabil 16:177–182
23.
Elliott RA (2008) Poor adherence to medication in adults with rheumatoid arthritis: reasons and solutions. Dis Manag Health Outcomes 16:13–29CrossRef
24.
Gadallah MA, Boulos DN, Gebrel A, Dewedar S, Morisky DE (2015) Assessment of rheumatoid arthritis patients’ adherence to treatment. Am J Med Sci 349:151–156CrossRefPubMed
25.
Gross R, Graybill J, Wahezi D, Jordan NC, Putterman C, Blanco I (2014) Increased education is associated with decreased compliance in an urban multi-ethnic lupus cohort. J Clin Cell Immunol 5:215–230PubMedPubMedCentral
26.
Hromadkova L, Soukup T, Vlcek J (2015) Quality of life and drug compliance: their interrelationship in rheumatic patients. J Eval Clin Prac 21:919–924CrossRef
27.
Koneru S, Kocharla L, Higgins GC et al (2008) Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol 14:195–201PubMed
28.
Kumar K, Gordon C, Barry R, Shaw K, Horne R, Raza K (2011) ‘It’s like taking poison to kill poison but I have to get better’: a qualitative study of beliefs about medicines in Rheumatoid arthritis and Systemic lupus erythematosus patients of South Asian origin. Lupus 20:837–844CrossRefPubMed
29.
Kumar K, Raza K, Nightingale P et al (2015) Determinants of adherence to disease modifying anti-rheumatic drugs in White British and South Asian patients with rheumatoid arthritis: a cross sectional study. BMC Musculoskelet Disord 16:396CrossRefPubMedPubMedCentral
30.
Li P, Blum MA, Von Feldt J, Hennessy S, Doshi JA (2010) Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. Value Health 13:805–812CrossRefPubMed
31.
Loew L, Brosseau L, Kenny GP et al (2016) Factors influencing adherence among older people with osteoarthritis. Clin Rheumatol 35:2283–2291CrossRefPubMed
32.
Marchesoni A, Zaccara E, Gorla R et al (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann NY Acad Sci 1173:837–846CrossRefPubMed
33.
Morgan C, McBeth J, Cordingley L et al (2015) The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology 54:1780–1791CrossRefPubMedPubMedCentral
34.
Müller R, Kallikorm R, Põlluste K, Lember M (2012) Compliance with treatment of rheumatoid arthritis. Rheumatol Int 32:3131–3135CrossRefPubMed
35.
Neame R, Hammond A (2005) Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology 44:762–767CrossRefPubMed
36.
Pascual-Ramos V, Contreras-Yanez I, Villa AR, Cabiedes J, Rull-Gabayet M (2009) Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. Arthritis Res Ther 11:R26CrossRefPubMedPubMedCentral
37.
Pasma A, van’t Spijker A, Hazes JM, Busschbach JJ, Luime JJ (2013) Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum 43:18–28CrossRefPubMed
38.
Pavelka K, Forejtova S, Stolfa J et al (2009) Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol 27:958–963PubMed
39.
Salaffi F, Carotti M, Di Carlo M, Farah S, Gutierrez M (2015) Adherence to anti-tumor necrosis factor therapy administered subcutaneously and associated factors in patients with rheumatoid arthritis. J Clin Rheumatol 21:419–425CrossRefPubMed
40.
Tesher MS, Onel KB (2012) The clinical spectrum of juvenile idiopathic arthritis in a large urban population. Curr Rheumatol Rep 14:116–120CrossRefPubMed
41.
Tuncay R, Eksioglu E, Cakir B, Gurcay E, Cakci A (2007) Factors affecting drug treatment compliance in patients with rheumatoid arthritis. Rheumatol Int 27:743–746CrossRefPubMed
42.
van den Bemt BJ, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, van Lankveld W (2009) Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol 36:2164–2170CrossRefPubMed
43.
Viller F, Guillemin F, Briancon S, Moum T, Suurmeijer T, van den Heuvel W (1999) Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol 26:2114–2122PubMed
44.
Wong M, Mulherin D (2007) The influence of medication beliefs and other psychosocial factors on early discontinuation of disease-modifying anti-rheumatic drugs. Musculoskelet Care 5:148–159CrossRef
45.
Zandman-Goddard G, Amital H, Shamrayevsky N, Raz R, Shalev V, Chodick G (2013) Rates of adherence and persistence with allopurinol therapy among gout patients in Israel. Rheumatology 52:1126–1131CrossRefPubMed
46.
Zwikker HE, van Dulmen S, den Broeder AA, van den Bemt BJ, van den Ende CH (2014) Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis. Patient Preference Adherence 8:1635–1645CrossRefPubMedPubMedCentral
47.
Agarwal S, Zaman T, Handa R (2009) Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Singapore Med J 50:686–692PubMed
48.
Bendtsen P, Bjurulf P, Trell E, Lindstrom F, Larsson JE (1994) Treatment perspectives in rheumatoid arthritis: a descriptive study in a Swedish healthcare district. PharmacoEconomics 5:399–407CrossRefPubMed
49.
De Cuyper E, De Gucht V, Maes S, Van Camp Y, De Clerck LS (2016) Determinants of methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol 35:1335–1339CrossRefPubMed
50.
Doddapaneni S, Shetty R, Sabih I, Maddali K, Khera K (2014) Assessment of medication adherence in rheumatoid arthritis patients in a tertiary care hospital. Value Health 17:A774CrossRefPubMed
51.
Kumar K, Raza K, Gill P, Greenfield S (2016) The impact of using musculoskeletal ultrasound imaging and other influencing factors on medication adherence in patients with rheumatoid arthritis: a qualitative study. Patient Preference Adherence 10:1091–1100CrossRefPubMedPubMedCentral
52.
Mjaavatten MD, Radner H, Yoshida K et al (2014) Inconsistent treatment with disease-modifying antirheumatic drugs: a longitudinal data analysis. J Rheumatol 41:2370–2378CrossRefPubMedPubMedCentral
53.
Chu LH, Kawatkar AA, Gabriel SE (2015) Medication adherence and attrition to biologic treatment in rheumatoid arthritis patients. Clin Ther 37(660–66):e8
54.
de Thurah A, Norgaard M, Johansen MB, Stengaard-Pedersen K (2010) Methotrexate compliance among patients with rheumatoid arthritis: the influence of disease activity, disease duration, and co-morbidity in a 10-year longitudinal study. Scand J Rheumatol 39:197–205CrossRefPubMed
55.
Li LM, Tessier-Cloutier B, Wang Y et al (2013) Assessing process of care in rheumatoid arthritis at McGill University hospitals. J Clin Rheumatol 19:175–179CrossRefPubMed
56.
Rashid N, Coburn BW, Wu YL et al (2015) Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. Journal Rheumatol 42:504–512CrossRef
57.
Xia Y, Yin R, Fu T et al (2016) Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis. Patient Preference Adherence 10:735–742PubMedPubMedCentral
58.
Bonafede M, Johnson BH, Tang DH, Shah N, Harrison DJ, Collier DH (2015) Etanercept-methotrexate combination therapy initiators have greater adherence and persistence than triple therapy initiators with rheumatoid arthritis. Arthritis Care Res 67:1656–1663CrossRef
59.
Contreras-Yanez I, Ponce De Leon S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V (2010) Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci 340:282–290CrossRefPubMed
60.
de Vlam K, Boone C, The Prove Study Group A (2015) Treatment adherence, efficacy, and safety of etanercept in patients with active psoriatic arthritis and peripheral involvement in Belgium for 66 months (PROVE study). Clin Exp Rheumatol 33:624–631PubMed
61.
Drenkard C, Dunlop-Thomas C, Easley K, Bao G, Brady T, Lim SS (2012) Benefits of a self-management program in low-income African-American women with systemic lupus erythematosus: results of a pilot test. Lupus 21:1586–1593CrossRefPubMed
62.
Hetland ML, Christensen IJ, Tarp U et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62:22–32CrossRefPubMed
63.
Kim G, Barner JC, Rascati K, Richards K (2016) Examining time to initiation of biologic disease-modifying antirheumatic drugs and medication adherence and persistence among texas medicaid recipients with rheumatoid arthritis. Clin Ther 38:646–654CrossRefPubMed
64.
Kristensen LE, Saxne T, Nilsson JA, Geborek P (2006) Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 8:R174CrossRefPubMedPubMedCentral
65.
Malaviya AP, Ostor AJ (2012) Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept. Patient Preference Adherence 6:589–596PubMedPubMedCentral
66.
Wong PK (2016) Medication adherence in patients with rheumatoid arthritis: why do patients not take what we prescribe? Rheumatol Int 36:1535–1542CrossRefPubMed
67.
Prudente LR, Diniz Jde S, Ferreira TX et al (2016) Medication adherence in patients in treatment for rheumatoid arthritis and systemic lupus erythematosus in a university hospital in Brazil. Patient Preference Adherence 10:863–870CrossRefPubMedPubMedCentral
68.
Aaltonen KJ, Turunen JH, Sokka T, Puolakka K, Valleala H (2016) A survey on the medication adherence to methotrexate among rheumatoid arthritis patients treated with self-administered biologic drugs. Clin Exp Rheumatol 34:694–697PubMed
69.
Cabrera-Marroquin R, Contreras-Yanez I, Alcocer-Castillejos N, Pascual-Ramos V (2014) Major depressive episodes are associated with poor concordance with therapy in rheumatoid arthritis patients: the impact on disease outcomes. Clin Exp Rheumatol 32:904–913PubMed
70.
Julian LJ, Yelin E, Yazdany J et al (2009) Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum 61:240–246CrossRefPubMedPubMedCentral
71.
Abobului M, Berghea F, Vlad V et al (2015) Evaluation of adherence to anti-osteoporosis treatment from the socio-economic context. Journal of medicine and life 8:119–123 (spec issue) PubMedPubMedCentral
72.
Flower C, Hambleton I, Campbell M (2016) The effect of psychosocial and neuropsychiatric factors on medication adherence in a cohort of women with systemic lupus erythematosus. J Clin Rheumatol 22:411–417CrossRefPubMed
73.
Iudici M, Russo B, Mitidieri M, Cuomo G, Valentini G (2015) Glucocorticoids in systemic sclerosis: patients’ beliefs and treatment adherence. Scand J Rheumatol 44:229–237CrossRefPubMed
74.
75.
Broderick JE, Stone AA, Smyth JM, Kaell AT (2004) The feasibility and effectiveness of an expressive writing intervention for rheumatoid arthritis via home-based videotaped instructions. Ann Behav Med 27:50–59CrossRefPubMed
76.
Durcan L, Clarke WA, Magder LS, Petri M (2015) Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol 42:2092–2097CrossRefPubMedPubMedCentral
77.
Geryk LL, Blalock S, DeVellis RF, Morella K, Carpenter DM (2016) Associations between patient characteristics and the amount of arthritis medication information patients receive. J Comm 21:1122–1130
78.
Abdul-Sattar AB, Abou El Magd SA (2015) Determinants of medication non-adherence in Egyptian patients with systemic lupus erythematosus: Sharkia Governorate. Rheumatol Int 35:1045–1051CrossRefPubMed
79.
Pascual-Ramos V, Contreras-Yanez I (2013) Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient’s perspective. BMC Musculoskelet Disord 14:336CrossRefPubMedPubMedCentral
80.
Bonafede M, Johnson BH, Princic N, Shah N, Harrison DJ (2015) Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. J Med Econ 18:376–389CrossRefPubMed
81.
Nasser-Ghodsi N, Harrold LR (2015) Overcoming adherence issues and other barriers to optimal care in gout. Curr Opin Rheumatol 27:134–138CrossRefPubMed
82.
Solomon DH, Tonner C, Lu B et al (2014) Predictors of stopping and starting disease-modifying antirheumatic drugs for rheumatoid arthritis. Arthritis Care Res 66:1152–1158CrossRef
83.
Wan SW, He HG, Mak A et al (2016) Health-related quality of life and its predictors among patients with rheumatoid arthritis. Appl Nurs Res 30:176–183CrossRefPubMed
84.
Carter EE, Barr SG, Clarke AE (2016) The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 12:605–620CrossRefPubMed
85.
Yap Angela Frances, Thiru Thirumoorthy Yu, Kwan Heng (2016) Medication adherence in the elderly. J Clin Gerontol Geriatrics 2016(10):1016
86.
Yap Angela Frances, Thiru Thirumoorthy Yu, Kwan Heng (2015) Systematic review of the barriers affecting medication adherence in older adults. Geriatrics Gerontol Int 2015(10):1111
87.
Goh XTW, Tan YB, Thirumoorthy T, Kwan YH (2016) A systematic review of factors that influence treatment adherence in paediatric oncology patients. J Clin Pharm Ther 42:1–7CrossRefPubMed
88.
Joplin S, van der Zwan R, Joshua F, Wong PKK (2015) Medication adherence in patients with rheumatoid arthritis: the effect of patient education, health literacy, and musculoskeletal ultrasound. Biomed Res Int 2015:150658CrossRefPubMedPubMedCentral
Metadata
Title
A systematic review of the barriers affecting medication adherence in patients with rheumatic diseases
Authors
Hendra Goh
Yu Heng Kwan
Yi Seah
Lian Leng Low
Warren Fong
Julian Thumboo
Publication date
01-10-2017
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 10/2017
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-017-3763-9

Other articles of this Issue 10/2017

Rheumatology International 10/2017 Go to the issue

Genes and Disease

Association of ADAM 12 polymorphisms with the risk of knee osteoarthritis: meta-analysis of 5048 cases and 6848 controls

Observational Research

Analgesic use in patients with knee and/or hip osteoarthritis referred to an outpatient center: a cross-sectional study within the Amsterdam Osteoarthritis Cohort

Review on Health Services Research

Leveraging the electronic health record to improve quality and safety in rheumatology

Observational Research

A single recent injury is a potent risk factor for the development of accelerated knee osteoarthritis: data from the osteoarthritis initiative

Observational Research

Posttraumatic stress disorder and correlates of disease activity among veterans with ankylosing spondylitis

Genes and Disease

Association of HLA‑B27 and its subtypes with ankylosing spondylitis and clinical manifestations of ankylosing spondylitis in different HLA-B27 subtypes: comment on the article by Lin et al.
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits